News and Updates

Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.

Learn the basics about autoimmune disease, including prevalence in the U.S., possible causes, and why they are often called "invisible."

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

Breakthrough T1D created a guide for sensor issues, from what to do if symptoms and CGM reading do not match to how to get a replacement.

What’s happening? Continuous ketone monitoring (CKM) is on its way. A new paper in The Lancet Diabetes & Endocrinology, titled “International expert recommendations on the application and utility of continuous ketone monitoring for people with diabetes,” was published by Breakthrough T1D and expert collaborators, spearheaded by our Chief Medical Officer, International, Thomas Danne, M.D., Ph.D. […]

Support and resources for issues with continuous glucose monitors (CGMs), including inaccurate readings and faulty sensors.

How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]

Closing the gap between access to and adoption of type 1 diabetes therapies is a mission priority. Chris Dunn represents these efforts in action.

What’s happening? Today, Breakthrough T1D co-hosted an event with leading international diabetes organizations to discuss cardiovascular disease (CVD) and type 1 diabetes (T1D)—where we are, challenges that remain, and how we can work together in Europe and beyond to address this need for the T1D community. The focus of the event: Doing more for CVD […]

Bonjour from Montreal, Canada, where the latest and greatest in type 1 diabetes (T1D) research was presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 51st Annual Conference. ISPAD is a yearly highlight of the T1D conference calendar, and this year was no exception. Scientists, clinicians, researchers, industry members, people with diabetes, and […]